AI & Diagnostics Software in California

Mindera Health develops precision medicine diagnostics for dermatological conditions, specifically psoriasis. The company's flagship product, Mind.Px™, is a non-invasive diagnostic patch that captures thousands of RNA transcripts from a penny-sized skin sample in approximately five minutes. The device employs Dermal Intelligence™ technology to enable scalable collection and analysis of individualized genetic information, providing actionable, data-driven treatment guidance for patients, providers, and payers. Mind.Px is designed to support biologic therapy selection for psoriasis patients, reducing trial-and-error treatment approaches. The company markets directly to healthcare providers and patients, offering physician resources, online test ordering, and patient education materials. Mindera Health has received regulatory approval from the New York State Department of Health as of April 2026, enabling national availability across all 50 states. The platform combines genomic RNA analysis with clinical dermatology to support precision treatment decisions. Target users include dermatologists, rheumatologists, and other providers managing psoriasis patients seeking to optimize biologic therapy outcomes.

Phase Scientific International Limited develops proprietary diagnostic technology and rapid testing solutions for early disease detection, with focus on cancer and infectious diseases. The company's core innovation is PHASIFY™, a molecular detection platform that enables faster, easier identification of target biomarkers compared to conventional diagnostics. PHASIFY™ powers three product and service lines: INDICAID® at-home rapid tests for point-of-care use; INDICAID lab™ at-home laboratory testing kits; and PHASE lab, a clinical laboratory service offering cancer and infectious disease testing. Recent product launches include FebriDx®, a respiratory pathogen test awarded FDA CLIA waiver (March 2026), and urine-based HPV screening for cervical cancer detection. The company markets solutions for cancer screening, cervical health monitoring, and respiratory/infectious disease diagnostics. Manufacturing and regulatory capabilities include FDA CLIA certification and active clinical research partnerships. The company has raised $34 million Series A funding and maintains operations in Asia and North America, positioning itself as an innovator in preventive diagnostics and non-invasive biomarker detection.

Alife Health is an AI-powered software platform designed to modernize and optimize the in vitro fertilization (IVF) process for fertility clinics. Founded in 2020 and based in San Francisco, the company offers a configurable ecosystem of clinical decision-support tools integrated with EMR systems. Key products include Embryo Assist™ for standardized embryo cataloging and grading (reducing nurse cryo calls by ~90%), Schedule Predict for ovarian retrieval capacity optimization (reducing overcapacity days by ~65%), Success Predictor for patient engagement and outcome monitoring, and Stim Assist for personalized gonadotropin dosing. The platform leverages interpretable machine learning models trained on fertility clinic data to provide actionable insights for embryologists, lab managers, and reproductive endocrinologists. Alife's solutions are trusted by major fertility networks including US Fertility, Ovation Fertility, Shady Grove Fertility, and others. The company is HIPAA-compliant and SOC 2 Type II certified, with peer-reviewed publications in Fertility and Sterility and RBMO validating clinical efficacy.

Veracyte is a global molecular diagnostics company specializing in genomic testing for cancer diagnosis, risk stratification, and treatment guidance. Founded in 2006 and headquartered in South San Francisco with operations in Austin, Texas, and Haifa, Israel, the company has impacted over 800,000 patients through its evidence-based portfolio of gene expression and genomic sequencing classifiers. Veracyte's core platform integrates transcriptomics, genomics, AI-assisted bioinformatics, and clinical outcome data to deliver actionable insights for thyroid, prostate, breast, bladder, and lung cancers. Key validated tests include Afirma (thyroid nodule classification), Decipher (prostate and bladder genomic assessment), and Prosigna (breast cancer risk of recurrence). The company's diagnostic innovation engine supports both LDT laboratory developed tests and collaborative R&D with biopharmaceutical partners, backed by >600 peer-reviewed publications and >35 prospective clinical trials.

CTK Biotech, Inc. is a California-based biotechnology company specializing in the development and manufacturing of innovative point-of-care (POC) diagnostic test kits and immunodiagnostic tools for the global in vitro diagnostics (IVD) community. Founded in 1997, CTK manufactures portable, easy-to-use rapid diagnostic tests that enable quick and accurate disease diagnosis in clinical, remote, and underserved settings. The company maintains in-house production of recombinant antigens and antibodies, ensuring product quality and compliance with U.S. cGMP standards and WHO approval. CTK's product portfolio includes rapid tests for influenza A/B, H. pylori, syphilis, dengue, RSV, and HIV, with multiple products achieving CE-IVDR marking. As a wholly-owned affiliate of SSI Diagnostica A/S Group, CTK employs approximately 228 personnel and generates ~$28.2M in annual revenue, serving B2B diagnostics customers worldwide.

Hukui Biotechnology Co., Ltd. is a Contract Development and Manufacturing Organization (CDMO) established in 2013, specializing in electronic and medical device design, engineering, and manufacturing. Headquartered in Taipei, Taiwan, with GMP-certified production facilities in Zhubei, Taiwan and Chongqing, China, plus a U.S. business office in San Jose, California, Hukui leverages deep semiconductor and electronics industry expertise to serve medtech companies globally. The company offers three core solution areas: Medical AI Devices & Senior Care (telemedicine and AI-driven diagnostics), Medical Images & Endoscopy (ultrasound and endoscopic systems), and Point-of-Care Technologies (handheld diagnostic solutions). Hukui provides comprehensive services including design engineering, product development, small to large-scale manufacturing, and global regulatory affairs registration across FDA (U.S.), TFDA (Taiwan), and NMPA (China) jurisdictions. Manufacturing capabilities include regular working rooms, cleanrooms (Class 10,000 and Class 100,000), dedicated QC labs, and warehousing. The company is positioned as a partner for transforming groundbreaking technologies into fully engineered medical solutions, with emphasis on meticulous manufacturing processes and punctual delivery. Hukui participates in major industry exhibitions including MEDICA, MD&M, and regional trade shows.

Silver Lake Research Corporation develops, manufactures, and markets rapid point-of-care diagnostic test kits with proprietary EAP™-derived monoclonal antibodies. Founded in 1992, the company specializes in lateral flow immunoassays that deliver laboratory-grade accuracy and sensitivity in minutes at the point of care. The company operates an ISO 13485-compliant, FDA-registered US manufacturing facility—one of the largest independent automated production lines for lateral flow tests—enabling high-volume production of both proprietary products and contract-manufactured diagnostics. Key product lines include HemoTypeSC (hemoglobin phenotyping for sickle cell disease screening), WaterSafe (drinking water quality testing), and RapidBac (rapid urinary tract infection detection requiring no instrumentation). The company has marketed 150+ products and produced over 15 million test strips globally. Services include custom immunoassay development, bespoke assays for specific instruments, and private-label manufacturing. Silver Lake Research serves clinical laboratories, point-of-care testing environments, and contract manufacturing customers. The company emphasizes tangible innovation in antibody development and manufacturing partnerships, positioning itself as a turnkey solution provider for rapid diagnostic platforms.

Lady Technologies is a women's health company developing a proprietary vaginal health platform centered on cervical mucus biomarker analysis. Their flagship product, kegg, is an intravaginal device that measures cervical mucus changes to identify fertile windows, provide pelvic floor training, and deliver actionable health insights. The platform currently focuses on fertility tracking and conception support, with clinical applications extending to non-hormonal contraception, infection detection, and pelvic floor health monitoring. kegg has supported over 50,000 women on their fertility journeys. The company emphasizes a data-driven, personalized approach to women's health by collecting and analyzing the largest known dataset on cervical mucus patterns. Lady Technologies is building a broader vaginal health ecosystem with potential for expanded diagnostic and therapeutic applications beyond fertility.

Tally Surgical, Inc. designs and manufactures a proprietary RFID-based retained surgical sponge detection system. The company's flagship product uses unique RFID technology embedded in surgical sponges to prevent retained foreign objects (RFOs), one of the most common adverse events in surgery. The system operates at up to 900+ scans per second and includes a proprietary FIND MODE feature to rapidly locate missing sponges in the operating room. Tally's solution addresses a critical patient safety concern: retained surgical sponges affect an estimated 92% of patients with permanent or temporary injury and carry an average indemnity payout of $473,000 per incident, plus corrective surgery costs averaging $77,512. The company positions its cost-competitive offering as an alternative to manual counting and existing technologies. Tally Surgical serves hospital operating rooms and surgical centers seeking to reduce never-events and associated liability while improving clinical outcomes. The company is headquartered in Aliso Viejo, California and is led by industry veterans who previously developed first-generation retained sponge prevention products.

Nerbio Medical Software Platforms manufactures and delivers the iTOF®, the world's first and only FDA-cleared, wireless, app-controlled quantitative train-of-four (TOF) neuromuscular monitoring device. The iTOF connects to smartphones and tablets to provide real-time, quantitative neuromuscular assessments in perioperative settings without requiring bulky standalone equipment or significant capital investment. The platform integrates advanced AI assistance to help clinicians accurately guide neuromuscular blocking agent dosing and determine optimal post-operative recovery timing. Delivered as a Medical Device as a Service subscription model, iTOF operates at minimal daily cost (approximately $1/day) with full replacement warranty and no disposable costs. Clinical data demonstrates 10% improvement in operating room throughput, 15–30% reduction in neuromuscular blocking agent use, and significant reduction in post-operative residual blockade complications. The device is portable, battery-operated, hands-free, and compatible with both iOS and Android platforms. Nerbio is building a comprehensive platform of mobile, AI-powered monitoring solutions for perioperative and critical care environments.

Intuitive Surgical, Inc. is a global leader in robotic-assisted surgical systems and digital health solutions. The company manufactures the da Vinci family of robotic surgery platforms, which enable minimally invasive surgical procedures across multiple specialties including general surgery, urology, gynecology, cardiothoracic, and orthopedics. Core product lines include the da Vinci 5 (advanced integrated robotic platform with surgeon console and patient cart), the da Vinci SP (single-port robotic system for new surgical approaches), and the Ion robotic bronchoscopy system for lung cancer diagnosis and biopsy. Intuitive also manufactures da Vinci instruments and accessories designed for precision and ergonomic control. Beyond hardware, the company provides digital solutions including My Intuitive (data analytics and insights platform for surgical teams) and SimNow (surgeon training and simulation software). The company operates a global infrastructure with expanded direct operations in Europe and provides 24/7 service and support. Intuitive's systems are used in hospitals worldwide for minimally invasive surgery, and the company has established itself as the market leader in robotic-assisted surgical technology since its founding in 1995. The platform emphasizes surgeon autonomy, precision, and patient outcomes through advanced visualization and control systems.

BioLegend is a biomedical research company specializing in the development and manufacturing of research reagents and antibodies for scientific investigations. The company operates a modern manufacturing facility in San Diego, California, and offers a comprehensive portfolio including monoclonal and polyclonal antibodies, immunoassay solutions, recombinant proteins, magnetic cell separation products, and single-cell proteogenomics reagents. BioLegend serves research institutions, pharmaceutical companies, and clinical laboratories across multiple therapeutic areas including neuroscience, oncology, immunology, stem cell research, and clinical diagnostics. The company has acquired the Covance antibody product portfolio to strengthen its neuroscience offerings and collaborates with leading research organizations such as The Michael J. Fox Foundation for Parkinson's Research and Illumina. BioLegend provides IVD (in vitro diagnostic) reagents and ASR (Analyte Specific Reagent) products for immunohistochemistry, immunophenotyping, and flow cytometry applications. The company emphasizes quality manufacturing, expert technical support, and custom product development services to support precision medicine, oncology, and biomedical discovery.

Cognoa is a pediatric behavioral health company developing AI-powered digital diagnostics and therapeutics for early childhood developmental conditions, with a focus on autism spectrum disorder. The company's flagship product, Canvas Dx™, is the first FDA-authorized digital diagnostic aid for autism in children aged 1.5 to 6 years, enabling remote evaluation and rapid diagnosis within days rather than months or years. Canvas Dx combines analysis of parent questionnaires and child behavior video to provide objective, data-driven diagnostic support that reduces diagnostic delays, healthcare costs, and disparities in care access—particularly for underserved and minority populations. The platform has achieved reimbursement coverage through Highmark Insurance and multiple state Medicaid programs. Beyond autism diagnostics, Cognoa is expanding its AI platform to address other pediatric behavioral health conditions including ADHD and anxiety, with a commitment to equitable, early intervention in developmental health assessment and treatment.